Overview

Study Of CP-751,871 In Combination With Cisplatin And Gemcitabine In Chemotherapy-Naïve Patients With Advanced Non-Small Cell Lung Cancer

Status:
Completed

Trial end date:
2010-03-01

Target enrollment:

Participant gender:

Summary

CP 751,871 is a fully human monoclonal antibody against the Insulin-Like Growth Factor 1 Receptor (IGF-1R). Preclinical and clinical data indicate that CP 751,871 augments the anti-tumor activity of chemotherapy. This study will identify the Maximal Tolerated Dose of CP 751,871 (or the Maximal Feasible Dose) in combination with standard gemcitabine-cisplatin chemotherapy for the treatment of advanced Non-Small Cell Lung cancer.

Phase:

Phase 1

Details

Lead Sponsor:

Pfizer

Treatments:

Antibodies, Monoclonal
Cisplatin
Gemcitabine
Pemetrexed